Premium
Solution Structure and In Silico Binding of a Cyclic Peptide with Hepatitis B Surface Antigen
Author(s) -
Muhamad Azira,
Ho Kok Lian,
A. Rahman Mohd. Basyaruddin,
Uhrín Dušan,
Tan Wen Siang
Publication year - 2013
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12120
Subject(s) - peptide , cyclic peptide , chemistry , in silico , docking (animal) , epitope , stereochemistry , antigen , biology , biochemistry , medicine , genetics , nursing , gene
A specific ligand targeting the immunodominant region of hepatitis B virus is desired in neutralizing the infectivity of the virus. In a previous study, a disulfide constrained cyclic peptide cyclo S 1 , S 9 C ys‐ G lu‐ T hr‐ G ly‐ A la‐ L ys‐ P ro‐ H is‐ C ys ( S 1 , S 9 ‐cyclo‐ CETGAKPHC ) was isolated from a phage displayed cyclic peptide library using an affinity selection method against hepatitis B surface antigen. The cyclic peptide binds tightly to hepatitis B surface antigen with a relative dissociation constant ( K D rel ) of 2.9 n m . The binding site of the peptide was located at the immunodominant region on hepatitis B surface antigen. Consequently, this study was aimed to elucidate the structure of the cyclic peptide and its interaction with hepatitis B surface antigen in silico . The solution structure of this cyclic peptide was solved using 1 H , 13 C , and 15 N NMR spectroscopy and molecular dynamics simulations with NMR ‐derived distance and torsion angle restraints. The cyclic peptide adopted two distinct conformations due to the isomerization of the Pro residue with one structured region in the ETGA sequence. Docking studies of the peptide ensemble with a model structure of hepatitis B surface antigen revealed that the cyclic peptide can potentially be developed as a therapeutic drug that inhibits the virus–host interactions.